News
AZ gets closer to Ionis, licensing amyloidosis drug in $3.6b...
AstraZeneca has snapped up another Ionis-discovered drug for its pipeline, this time phase 3 candidate eplontersen for the disease transthyretin amyloidosis (ATTR).
